Llanda, Florida C.
HRN: 22-59-28 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/15/2023
CEFUROXIME 1.5GM (VIAL)
03/15/2023
03/21/2023
IV
1.5gm
Q8
Soft Tissue Mass Excision
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes